C-OHQ7ImmuneBridge
HSC expansion, allogeneic cell therapy, ML screening
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-OHQ7
C-OHQ7C-OHQ7HSC expansion, allogeneic cell therapy, ML screening
0-100 chain-logic scale · 15 dimensions · scored on public evidence
3rd Donor Selection & Cell Source Summit | pharmaphorum Skip to main content Saturday 27 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research & Development
2022 Agenda October 5-7 | Arizona Biltmore Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attendees Contact Home Registration Innovation Spotlights Accommodations Sponsors Partnering Agenda About the Event Event FAQs Media Toolkits Attende
Agenda - Thursday 24th September - Conference Day Two | Cell & Gene Therapy International You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. September 22-25, 2026 as part of Biotech Week Boston Hynes Convention Center Boston, MA Home home Agenda & Progra … l Rashed Harun - Scientist , Genentech 5:00pm - 5:30pm Case Study from Arcellx: Application of MOI Titrations to Evaluate Vector Lots and Aid Process Decisions and Process Control Brian Murphy - VP Cell Process Science , Arcellx 4:30pm - 5:00pm Effective Tech Transfer of Manufacturing Processes to CDMO Partners Hunter Reese - Senior Scientist , AskBio 5:00pm - 5:30pm Analytical Control Strategy for Successful Method Transfer to Commercial Testing Lab Rajeev Boregowda - Associ
Eda Altiok PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Eda Altiok PhD Former HEAD OF PRODUCT at ImmuneBridge Inc. Eda Altiok PhD 's Executive Work History Past To view Eda Altiok PhD's complete executive work history, sign up now Eda Altiok PhD 's Biography Eda is a bioengineer and scientist by training turned product professional. She's lead engineering teams through all sta … y Officer , ImmuneBridge Inc. Peretz Partensky Former Venture Partner , PIONEER FUND Sumiti Jain Former CHIEF SCIENTIFIC OFFICER , ImmuneBridge Inc. Featured Profile Eda Altiok PhD Former HEAD OF PRODUCT at ImmuneBridge Inc. Eda Altiok PhD 's Executive Work History Past To view Eda Altiok PhD's complete executive work history, sign up now Eda Altiok PhD 's Biography Eda is a bioengineer and scientist by training turned product professional. She's lead engineering teams throug … y Officer , ImmuneBridge Inc. Peretz Partensky Former Venture Partner , PIONEER FUND Sumiti Jain Former CHIEF SCIENTIFIC OFFICER , ImmuneBridge Inc. Log In | Sign Up Executive Engagement Insights in Your Inbox Level up your strategy with articles, updates, and success stories in the ExecAtlas newsletter. Subscribe
ImmuneBridge - M Ventures Zum Inhalt springen Wegweiser About Us Portfolio Team Career News Contact Zur Startseite wechseln "> ImmuneBridge Next generation allogenic NK cell therapy platform ImmuneBridge is developing the next generation of allogeneic cellular medicines, starting with NK cell-based immunotherapies. ImmuneBridge’s proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency—to create a consistent and abundant cellular source for immunotherapies. Based in San Francisco, ImmuneBridge is led by Nina Horowitz, CEO and Ru
ImmuneBridge Home Technology Team News Contact Rui Tostoes, PhD Chief Technology Officer Team Members Bio Rui Tostoes is an accomplished scientist and creative leader, with a passion for product and people development in cell therapy and bioprocessing. Through his work in MilliporeSigma and FloDesign Sonics, he is experienced in matrix work with functional areas of R&D, Product Development and Commercial in delivering successful product development and customer program execution. PhD: MIT, Portugal. Contact Us [email protected] 2122 Bryant St, San Francisco, CA 94110 Name Email Messag
ASHI 51st Annual Meeting Skip to main content Toggle navigation Search Home Tweet Print Nina Horowitz, PhD CEO ImmuneBridge San Francisco, CA Nina Horowitz, PhD, is a bioengineer and scientific leader committed to advancing immunotherapies that can cure cancer and other serious diseases. She currently serves as Chief Executive Officer at ImmuneBridge, where she is driving the development of next-generation cell therapies with a focus on safety, accessibility, and broad clinical impact. Nina joined ImmuneBridge in 2022, initially leading NK cell therapy research before stepping into the CSO and
ImmuneBridge Home Technology Team News Contact Nina Horowitz, PhD Chief Executive Officer Team Members Bio Nina Horowitz is a bioengineer with research experience in disciplines ranging from evolutionary biology to cancer immunology. She worked in laboratories at Williams College, Mount Sinai, Boston University, and Stanford University before joining the ImmuneBridge team. Her doctoral research centered around the uses of engineered natural killer cells for solid tumor immunotherapy. BA: Williams College. MS, PhD: Stanford University. Contact Us [email protected] 2122 Bryant St, San Franc
ImmuneBridge - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks
Oliver Zill PhD - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Oliver Zill PhD Former Vice President Of Computational Biology at ImmuneBridge Inc. Oliver Zill PhD 's Executive Work History Past To view Oliver Zill PhD's complete executive work history, sign up now Oliver Zill PhD 's Biography Oliver Zill is an experienced manager and team builder with >20 years of experience in o … y Officer , ImmuneBridge Inc. Peretz Partensky Former Venture Partner , PIONEER FUND Eda Altiok PhD Former HEAD OF PRODUCT , ImmuneBridge Inc. Sumiti Jain Former CHIEF SCIENTIFIC OFFICER , ImmuneBridge Inc. Featured Profile Oliver Zill PhD Former Vice President Of Computational Biology at ImmuneBridge Inc. Oliver Zill PhD 's Executive Work History Past To view Oliver Zill PhD's complete executive work history, sign up now Oliver Zill PhD 's Biography Oliver Zill is an experie … y Officer , ImmuneBridge Inc. Peretz Partensky Former Venture Partner , PIONEER FUND Eda Altiok PhD Former HEAD OF PRODUCT , ImmuneBridge Inc. Sumiti Jain Former CHIEF SCIENTIFIC OFFICER , ImmuneBridge Inc. Log In | Sign Up Executive Engagement Insights in Your Inbox Level up your strategy with articles, updates, and success stories in the ExecAtlas newsletter. Subscribe
{"_waf_bd8ce2ce37":"VTUpP32EDEy1aXGCzRnFL6DRuTdiH3Z6gb33Ssgg+Aw="} 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
ImmuneBridge Home Technology Team News Contact Jesse Cotari, PhD Scientific Advisor Advisory Board Bio Jesse Cotari is an immunologist whose early work at Memorial Sloan Kettering Cancer Center focused on computational models of immune-cell behavior. As the scientific founder of ImmuneBridge, he led development of the company’s HSC expansion and differentiation platform. He is now the founder and CEO of Ampliment, a company using multimodal AI to modernize laboratory work. Contact Us [email protected] 2122 Bryant St, San Francisco, CA 94110 Name Email Message Thank you! Your submission ha
ImmuneBridge Inc. - Executive Bio, Top Executies, and Transitions - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Organization ImmuneBridge Inc. immunebridge.com Company Details Description ImmuneBridge is developing allogeneic immunotherapies for cancer. ImmuneBridge's key innovation fosters the development of immune stem cells obtained from cord blood and creates a fresh, adaptable, reliable, and plentiful cellular source for immuno … link. Alex is also on the board of advisors of Strategy Capital, the investment fund of Hamilton Helmer, author of Seven Powers. Previously, Alex was an entrepreneur-in-residence at Founders Fund, where he led the diligence processes for investments in SpaceX. He also founded Shop.com, a shopping and comparison website, which he eventually sold to Altura Ventures, Virtual Office, one of the first companies to register commercially valuable domain names, and Interband, an adve … link. Alex is also on the board of advisors of Strategy Capital, the investment fund of Hamilton Helmer, author of Seven Powers. Previously, Alex was an entrepreneur-in-residence at Founders Fund, where he led the diligence processes for investments in SpaceX. He also founded Shop.com, a shopping and comparison website, which he eventually sold to Altura Ventures, Virtual Office, one of the first companies to register commercially valuable domain names, and Interband, an adve
ImmuneBridge - 6th iPSC Drug Development Summit Skip to content Free to Attend for Biopharma & Academics* September 9-10, 2026 | Boston, MA About About the Summit FAQs Poster Session Content Hub iPSC Development in the Last 12 Months: Why This Year Matters More Than Most Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Day One Day Two Why Partner Why Partner Partners Media Partners Take Part Pricing & Registration Venue & Accommodation Contact Us Event Guide Register About About the Summit FAQs Poster Session Content Hub iPSC Development in the Last 12 Month
Blog Home Technology Team News Contact Blog News & Announcements Read about our work. Categories Publications Coverage Announcements Announcements Linkedin ImmuneBridge Raises $7.7M ImmuneBridge’s platform screens and manufactures high-quality allogeneic immune cells at commercial scale without sacrificing quality, in order to decrease cell therapy costs and improve their efficacy. Read more Read more Coverage Linkedin Interview with Dr. Rui Tostoes | News Medical Life Sciences We have two defined goals that contribute to our mission of making affordable and accessible cell therapy cures:
ImmuneBridge Home Technology Team News Contact Home Technology Team News Contact Home Technology Team News Contact All Posts NK Cells and Curing Cancer with Dr. Nina Horowitz Published on September 13, 2022 Sep 13, 2022 Our CEO, Dr. Nina Horowitz – then Head of R&D, NK– was interviewed on Axial podcast about NK cell biology, her academic career, and her motivation to find novel cures for the patients who need them. About Axial Axial partners with great founders and inventors. We invest in early-stage life sciences companies such as Appia Bio and Seranova Bio often when they are no more t
ImmuneBridge Chooses Sapio Sciences Electronic Lab Notebook to Modernize and Scale Enterprise Data Management --> --> 0 News Interviews Guest Post Featured Article Technology Hardware and Networks 5G Technology IoT Business Technology Digital Transformation Cloud Computing & Mobility Analytics Big Data SaaS and PaaS IaaS Artificial Intelligence Deep Learning Machine Learning Computer Science Data Science Augmented Reality Cognitive Technology Quantum Computing Fintech HealthTech BioTech Healthcare Analytics Healthcare IoT Smart Medical Devices Telehealth & Telemedicine Information and
042: Jesse Cotari & Peretz Partensky - Chief Scientific Officer and CEO of ImmuneBridge --> details-tag#clickAway keydown.esc@window->details-tag#close:passive" class="group"> Home Episodes About Think Like A Founder Home Episodes About + Follow players--transcripts#highlightSegment"> Think Like A Founder Think Like a Founder is a series of conversations with leaders, thinkers, inventors, revolutionaries, problem-solvers, and smart, nice people. Hosted by Maureen Taylor, co-founder of SNP Communications, this podcast dives deeper into a founder’s mindset and mentality -- what makes them ti
Podcast with Jesse Cotari & Peretz Partensky, ImmuneBridge Skip to content About What We Do Training Coaching Creative Studio Comms Contact Newsroom About What We Do Training Coaching Creative Studio Comms Contact Newsroom Search Start a conversation SF ∞ WORLDWIDE LISTEN. LEAD. INSPIRE. Podcast with Jesse Cotari & Peretz Partensky – Chief Scientific Officer and CEO of ImmuneBridge Think Like A Founder December 23, 2021 Jaselin Drown On Season 4 Episode 9 of the Think Like A Founder podcast , Maureen Taylor speaks with Jesse Cotari and Peretz Partensky. Jesse is the Chief Scient … n? Coaching Training Creative Studio Comms What else would you like to discuss? Submit Hyatt’s LEAD By Example: a podcast learning experience Play Pause 0:00 0:00 Let’s talk about your goals. A short, no-pressure conversation to understand what you’re working on and share a recommendation. After you submit, we’ll email you within one business day with a couple time options. First Name Last Name Work Email Company Role/Title Request time options No spam. No pressure. If it’s n … l marketing video to help raise awareness and adoption of Hyatt’s new Glasswing application, which tracks real-time financial data, KPIs, and other core metrics for owners and operators. From conducting the interviews, to coaching the speakers on camera and editing the video, SNP owned the content creation at each step of production. Back in 2013, Asana was still a young company and some of their managers were experiencing leadership roles for the first time. So they needed t … st Name Title Company Email Phone Number Additional Information By clicking on "Submit", you agree to the SNP Privacy Policy and communication from SNP Communications through the contact information listed. Submit Trainings Please enable JavaScript in your browser to complete this form. Please enable JavaScript in your browser to complete this form. Name * Phone * Company Name * Email * Number of Particpants * 1-5 6-5 11-15 16+ Courses (Select all that apply) I’m not su … ther Layout you Name What else would you like us to know? By clicking on “Submit”, you agree to the SNP Privacy Policy and communication from SNP Communications through the contact information listed. Submit
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Due Diligence & M&A — AI Agent Workflows for Legal Website CategorizationAPI Visit Main Website Home 105% Theme Overview Due Diligence & M&A Litigation Intelligence Compliance Monitoring Intellectual Property Contract Intelligence E-Discovery Regulatory Affairs Client Development Risk Management Knowledge Management These workflows display realistic demo data for demonstration. In production, the agents connect to your real legal services data via MCP services or CSV import. Deployment Options The entire platform is available as a self-hosted solution or managed service Self-Hosted REC … AI Search Visibility Finance & Professional Banking Crypto & Web3 Hedge Fund Insurance Private Equity & VC Consulting Education HR & Staffing Legal & Compliance Non-Profit Professional Services Real Estate Technology & Media Ad-Tech Cloud Security Cybersecurity Network Security SaaS & Software Telecommunications Digital Media Entertainment Gaming & Esports Media & Broadcasting Sports & Fitness Healthcare & Commerce Biotech Healthcar
EvolveImmune Therapeutics - aVenture Company Research Home Research Loading aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions. aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our
%PDF-1.7 %���� 3353 0 obj > endobj 3375 0 obj >/Encrypt 3354 0 R/Filter/FlateDecode/ID[ ]/Index[3353 33]/Info 3352 0 R/Length 103/Prev 4714802/Root 3355 0 R/Size 3386/Type/XRef/W[1 3 1]>>stream h�bbd```b``�"�~�H�W R�D�2�H�`rX�L�U�u��3��L0;I L�W�H u��H |�g��P�������$���?���? xnb endstream endobj startxref 0 %%EOF 3385 0 obj >stream B��ef�D���`�?��5 l�tUv;V�8e\r �^� ����`3�b�d���4Mg����\�K�� �3�x�y�vWy|7Qq���gk�v1U�V�����S�ɋ�ʏ�&�d�@�g"r���̕s�ށ��5�u��.g�M��C6/���g����\@j ۂ��j� �.|���Y;%.���#����A�����g_��JrN��K��Z� �K Gp�Q��z[�J���?���r�\��ȗ� Bn��mQ.��|9Ψ�t"�ϰ�
I'm excited to announce the... - BioInformant Worldwide LLC Facebook Log In BioInformant Worldwide LLC's Post BioInformant Worldwide LLC September 12, 2025 · Shared with Public I'm excited to announce the 5th iPSC Drug Development Summit (Oct 1–2, 2025, Boston), the industry’s leading forum advancing iPSC-derived therapies hosted by Hanson Wade. https://ipsc-therapies-summit.com/about/about-event/?utm_source=external&utm_medium=email&utm_campaign=other-who-what-why&utm_content=media-partner/other-bioinformant/paid/em-01/ev-59815 With 30+ speakers from pharma, biotech
Deverra Therapeutics - aVenture Company Research Home Research Loading aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions. aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data
S. Alexander Jacobson | 137 Ventures all team Meet the team backing founders and driving growth. 01/ Team Explore a portfolio of high-growth, venture-backed companies. 02/ Portfolio Get in touch with the team or request more information. 03/ Contact Secure access for limited partners to view reports and updates. 04/ LP Login all team S. Alexander Jacobson Investment Partner S. Alexander Jacobson is a founder and investment partner of 137 Ventures. Alex is also a founding investor of ImmuneBridge, a biotech startup developing genetically enhanced immune cell therapies, and founding advisor to A … link. Alex is also on the board of advisors of Strategy Capital, the investment fund of Hamilton Helmer, author of Seven Powers. Previously, Alex was an entrepreneur-in-residence at Founders Fund, where he led the diligence processes for investments in SpaceX. He also founded Shop.com, a shopping and comparison website, which he eventually sold to Altura Ventures, Virtual Office, one of the first companies to register commercially valuable domain names, and Interband, an adve
11th Innate Killer Summit Skip to content The site is part of the Hanson Wade division at Hanson Wade Group . About Us | Products | Contact Us Hanson Wade Conferences Limited is registered in England & Wales, number 16983906. Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH. Hanson Wade This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit. Returning March 2027 About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Med
Rui Tostoes - ImmuneBridge | BioProcess International Speaker You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. September 22-25, 2026 as part of Biotech Week Boston Hynes Convention Center Boston, USA Home home Agenda Speakers Sponsors & Exhibitors Start-Up
Rui Tostoes - ImmuneBridge | Cell & Gene Therapy International Speaker You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. September 22-25, 2026 as part of Biotech Week Boston Hynes Convention Center Boston, MA Home home Agenda & Program expand_more Full
Ten NK cell therapy companies to look out for this year Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by sec … patients. Last year, the biotech received the Immunology Innovation of the Year award in the 2023 BioTech Breakthrough Awards Program after its launch in 2020. Dragonfly Therapeutics Focused on bringing its NK cell therapies to the market, American company Dragonfly Therapeutics is developing a number of drug candidates based on its proprietary platform TriNKETs. TriNKETs engage both the innate and adaptive immune systems by activating NK cells and CD8 T cells, an
ASHI 51st Annual Meeting Skip to main content Toggle navigation Search Home 176 Views Like Tweet Print Featured Topic: From Code to Care: AI’s Promise & Pitfalls in Medicine Monday, October 6, 2025 12:30 PM - 5:00 PM US EDT Location: Grand Cypress D - F CE: .68 CEC / 4.5 CME Speaker(s) Medhat Askar, MD, PhD Associate Vice President For Clinical Affairs | Professor of Immunology Qatar University Doha, Ad Dawhah, Qatar Nicholas Borcherding, MD/PhD Assistant Professor Washington University St Louis Webster Groves, Missouri Nina Horowitz, PhD CEO ImmuneBridge San Francisco, CA Jana Lipkova, PhD As
Instagram Instagram Log In Sign Up Close Never miss a post from snpcomm Sign up for Instagram to stay in the loop. Sign up Log in snpcomm • Follow More options snpcomm 233w On the newest episode of Think Like A Founder, Jesse Cotari, Chief Scientific Officer, and Peretz Partensky, CEO, of ImmuneBridge, give their thoughts on… 💡Taking ownership 💡Being an outsider 💡How life is practice for life ImmuneBridge is an early-stage biotech company developing allogeneic immunotherapies for cancer. Check the link in our bio for the full episode or find Think Like A Founder on your favorite podcast app
Scaling Cell Therapy with ImmuneBridge's Proprietary Approach | Pranav Seshadri posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … apabilities work in harmony, the journey from concept → construct → therapeutic application becomes dramatically more efficient. 🎙️ Join our upcoming webinar to explore how unified, end‑to‑end capabilities can simplify development, reduce friction, and speed up the path to next‑generation CAR‑T therapies. 𝐋𝐞𝐭’𝐬 𝐭𝐮𝐫𝐧 𝐬𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐩𝐨𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 𝐢𝐧𝐭𝐨 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐫𝐞𝐚𝐥𝐢𝐭𝐲 — 𝐟𝐚𝐬𝐭𝐞𝐫 #RNA #LNP #CellTherapy #CART #BiotechInnovation #circRN
ImmuneBridge seeks to take on cancer with natural killer cells Skip to Main Content Eli Lilly Donald Trump Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series & Investigations Business Biotech Pharma Health Tech Health Insurance Hospitals … inkedin.com/in/jonathan-wosen-phd-b69172147/ Tags biotechnology Cancer STAT+ To submit a correction request, please visit our Contact Us page . Trending FDA gives generative AI in radiology two breakthrough designation… FDA gives generative AI in radiology two breakthrough designation nods Eli Lilly dives into hair loss treatments with investment… Eli Lilly dives into hair loss treatments with investment in AI startup Absci Eli Lilly gave extraordinary obesity d
ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Novel Natural Killer (NK) Cell-based Immunotherapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bus … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Novel Natural Killer (NK) Cell-based Immunotherapies April 11, 2023 | 4 min read Twitter LinkedIn Facebook Email Print ImmuneBridge today announced the close of an oversubscribed $12 million seed financing co-led by global investors Ins … dge.com . About M Ventures M Ventures is a strategic, corporate venture capital fund, with a mandate to invest in innovative technologies and products with the potential to significantly impact the business priorities of Merck KGaA, Darmstadt, Germany. From its headquarters in Amsterdam and offices in Germany, US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams … t has offices in London, Tel Aviv, and Palo Alto. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with right-sized, right-time practical, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on Twitter @insightpartners. View source version on businesswire.com: https://www.businesswire.com/new … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ImmuneBridge Chooses Sapio Sciences Electronic Lab Notebook to Modernize and Scale Enterprise Data Management - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital ImmuneBridge Chooses Sapio Sciences Electronic Lab Notebook to Modernize and Scale Enterprise Data Management November 20, 2023 | 3 min read Twitter LinkedIn Facebook Email Print ImmuneBridge, a developer of allogeneic, off-the-shelf cellular immunotherapies, has launched a new electronic lab notebook from Sa … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ImmuneBridge, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 24 Feb 2026 ImmuneBridge, Inc. Startups | Holding Company | 2018 | California, United States | 10-50 | www.immunebridge.com Startups | Holding Company | 2018 | California, United States | 10-50 | www.immunebridge.com Last update 24 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Other Diseases Natural Killer Cell Therapies Small molecule drug Disease domain score A glimps … , visit . About M Ventures M Ventures is a strategic, corporate venture capital fund, with a mandate to invest in innovative technologies and products with the potential to significantly impact the business priorities of Merck KGaA, Darmstadt, Germany. From its headquarters in Amsterdam and offices in Germany, US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams … t has offices in London, Tel Aviv, and Palo Alto. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with right-sized, right-time practical, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on Twitter @insightpartners. Immunotherapy 100 Deals associated with ImmuneBridge, Inc. Login to view … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
ImmuneBridge, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 24 Feb 2026 ImmuneBridge, Inc. Startups | Holding Company | 2018 | California, United States | 10-50 | www.immunebridge.com Startups | Holding Company | 2018 | California, United States | 10-50 | www.immunebridge.com Last update 24 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Other Diseases Natural Killer Cell Therapies Small molecule drug Disease domain score A glimps … , visit . About M Ventures M Ventures is a strategic, corporate venture capital fund, with a mandate to invest in innovative technologies and products with the potential to significantly impact the business priorities of Merck KGaA, Darmstadt, Germany. From its headquarters in Amsterdam and offices in Germany, US and Israel, M Ventures invests globally in transformational ideas driven by great entrepreneurs. M Ventures takes an active role in its portfolio companies and teams … t has offices in London, Tel Aviv, and Palo Alto. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with right-sized, right-time practical, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on Twitter @insightpartners. Immunotherapy 100 Deals associated with ImmuneBridge, Inc. Login to view … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
CTO to speak on #bioprocessing and scaling at summit | ImmuneBridge posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … ategy | Driving Translational‑to‑Commercial Strategy 8mo Cytiva receives ARPA-H award with ambition to help transform CAR-T cell therapy for solid tumors Cytiva Danaher Life Sciences Sadik Kassim Beate Dr. Mueller-Tiemann Cytiva receives ARPA-H award with ambition to help transform CAR-T cell therapy for solid tumors - Cytiva cytivalifesciences.com 10 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Cambridge Healthtech Institute 14,559 followers … R Are cell therapies the key to bridging the gap between discovery and clinical application? In the first-ever episode of Bioprocessing Unfiltered, Novo Nordisk Foundation Cellertaor’s Bo Wiinberg joins Landmark Bio’s Ran Zheng to discuss the promise and challenges of advancing cell therapy programs from pre-clinical to clinical stages. Listen & Subscribe https://lnkd.in/efiJC7uR …more 12 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Clinic
Cell therapy weekly: ImmuneBridge raises US$12 million in seed financing Skip to main content RegMedNet is part of Taylor & Francis Group. Taylor & Francis About us Our journals Our Digital Hubs Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK. Taylor & Francis Home Our journals Our journals Journal content Journal articles Follow us on social media Topics CAR-T Stem cells Cell therapy Gene therapy Gene editing … and Gene Therapies Advisory Committee will meet to review the biologics license application for a Duchenne muscular dystrophy gene therapy . The news highlights: ImmuneBridge raises US$12 million in seed financing CANbridge Pharmaceuticals to present data on AAV gene therapy for spinal muscular atrophy at ASGCT Annual Meeting US FDA to meet regarding biologics license application for Duchenne muscular dystrophy gene therapy ImmuneBridge raises US$12 million in seed financing … ght Partners (NY, USA) and M Ventures , the strategic corporate venture capital fund of Merck (NJ, USA). ImmuneBridge raised US$12 million in this round of financing, which will be utilized to build a screening dataset for indication-optimized NK cells, demonstrate scalable manufacturability and generate pre-clinical data for a lead product. “Cell therapy is a new pillar of medicine and is inextricably human. Cell therapy developers fear donor-to-donor variability, yet we hum … ay; Los Angeles, CA, USA). Read more US FDA to meet regarding biologics license application for Duchenne muscular dystrophy gene therapy A date has been announced for the meeting of the US FDA’s Cellular, Tissue and Gene Therapies Advisory Committee regarding the biologics license application for SRP-9001 (delandistrogene moxeparvovec). SRP-9001 is an investigational gene therapy for the treatment of Duchenne muscular dystrophy from Sarepta Therapeutics (OR, USA). “We look fo
ImmuneBridge Company Overview, Contact Details & Competitors | LeadIQ Learn more at LeadIQ.com Start free Insights Similar companies Tech Stack Media & News Email Format FAQ Insights Innovative Funding ImmuneBridge has recently secured $7.7 million in seed funding from prominent investors including NFX, One Way Ventures, and Insight Partners, indicating strong investor confidence and potential for funding future growth initiatives. Strategic Leadership The appointment of Nina Horowitz as CEO and the promotion of Dr. Rui Tostoes to CTO highlight a strategic leadership realignment focuse
Allogeneic Cellular Medicine Company ImmuneBridge Raises $12 Million VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 Allogeneic Cellular Medicine Company ImmuneBridge Raises $12 Million By Noah Long • Apr 14, 2023 Allogeneic Cellular Medicine Company ImmuneBridge Raises $12 Million ImmuneBridge – a biotechnology company using nature’s innate intelligence to fight cancer – announced the closing of an oversubscribed $12 million seed financing co-led by global investors Insight Partners and M Ventures (strategic corporate venture capital arm of Merc
ImmuneBridge appoints Rui Tostoes and Nina Horowitz (March 2026) Following ImmuneBridge? Get the free weekly executive digest The latest leadership moves, like ImmuneBridge’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime. Weekly Digest New leadership moves, summarized for you Straight to Inbox No login, no app to check — it comes to you Leadership Trends See who's moving and how much in your market Subscribe Free No credit card required Weekly executive digest Back to Executives Immune Bridge Promotes Dr. Nina Horowitz To C
Speakers - 11th Innate Killer Summit Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit. Returning March 2027 About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Media Partners Take Part Register Interest Contact Us Previous Event Guide Register Interest About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Media Partners Take Part Regi
ImmuneBridge Raises $12M from M Ventures and Insight Partners - M Ventures Zum Inhalt springen Wegweiser About Us Portfolio Team Career News Contact Zur Startseite wechseln Advancing Novel Natural Killer (NK) Cell-based Immunotherapies ImmuneBridge Raises $12M from M Ventures and Insight Partners 2023/04/11 Biotech company taps into human diversity for next-generation NK cell therapies. ImmuneBridge, a biotechnology company using nature’s innate intelligence to fight cancer, today announced the close of an oversubscribed $12 million seed financing co-led by global investors Insight Partners an
18 Silicon Valley Startups Raised $601M Last Week Edith Yeung Subscribe Sign in 18 Silicon Valley Startups Raised $601M Last Week Ouro Medicines Acquired by Gilead Sciences for $2.18B 15 Months after Launch Edith Yeung Mar 30, 2026 5 1 Share Happy Monday! Hugo Barra left Meta in 2021 only to return via Dreamer in 2026. Photo by Justin Sullivan/Getty Images Here are a few notable investments & acquisition last week: Ouro Medicines This $2.18B acquisition by Gilead Sciences is particularly notable as the company reached a $2 billion valuation in less than 18 months, marking it as one of the … $120 million in funding . The company was founded by Monograph Capital (UK bio fund) in partnership with GSK plc (UK pharma) to develop immune reset therapeutics for chronic immune-mediated diseases. It is also worth noting that Jaideep Dudani , the CEO of Ouro Medicines, previously served as a Principal at Monograph Capital. This development represents a significant milestone in the biotech sector. Dreamer As part of Meta’s recent acquisition of Dreamer - a store for agenti
S-1 1 d40026ds1.htm S-1 S-1 Table of Contents As filed with the Securities and Exchange Commission on February 12, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Reinvent Technology Partners Y (Exact name of registrant as specified in its charter) Cayman Islands 6770 98-1562265 (State or oth … ic market for our units, Class A ordinary shares or warrants. We intend to apply to list our units on The Nasdaq Capital Market (“Nasdaq”) under the symbol “RTPYU” on or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq. The Class A ordinary shares and warrants constituting the units will begin separate trading on the 52nd day following the date of this prospectus, subject t … nbsp; Our management team has unique experience with and insights into the application of transformative technologies, including artificial intelligence, autonomous driving, mobility, blockchain, robotics, and others. Market Opportunity We believe that the large quantity of late-stage private technology companies, against a backdrop of continued macroeconomic uncertainty and volatility, creates an ideal environment for our blank-check company and the differentiated advan … adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we ar … imposing any tax to be levied on profits, income, gains or appreciations shall apply to us or our operations and, in addition, that no tax to be levied on profits, income, gains or appreciations or which is in the nature of estate duty or inheritance tax shall be payable (1) on or in respect of our shares, debentures or other obligations or
ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Novel Natural Killer (NK) Cell-based Immunotherapies | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project | Infection | Springer Nature Link Skip to main content Advertisement Account Menu Find a journal Publish with us Track your research Search Saved research Cart Home Infection Article Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project Research Open access Published: 02 August 2023 Volume 52 , pages 139–153 ( 2024 ) Cite this article You have ful … article Download PDF Save article View saved research Infection Aims and scope Submit manuscript Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project Download PDF Berit Lange 1 , 2 na1 , Veronika K. Jaeger 3 na1 , Manuela Harries 1 , Viktoria Rücker 4 , Hendrik Streeck 5 , 6 , Sabine Blaschke 7 , Astrid Petersmann 8 , 9 , Nicole Toepfner 10 , Matthias Nauck 9 , 11 , Max J. Hass … for supporting the SchoolCoviDD19 (SchoolCoviDD19 (paedSAXCOVID) by a financial grant. We thank the Bavarian State Ministry of Health and Care/State Office for Health and Food Safety for supporting Wü-KiTa-CoV by a financial grant. We thank Josephine Schneider for her excellent organisation of the SchoolCoviDD19 (paedSAXCOVID) study. Funding Open Access funding enabled and organized by Projekt DEAL. IMMUNEBRIDGE is a research project funded by the Federal Ministry of Educatio … or Epidemic Outbreaks’ (LOKI), which is funded by the Initiative and Networking Fund of the Helmholtz Association (grant agreement number KA1-Co-08). It was further supported by the Federal Ministry of Education and Research (BMBF) via the RESPINOW (grant number: MV2021-012) and OptimAgent (grant number: MV2021-014) projects. Author information Author notes Berit Lange and Veronika K. Jaeger shared first authorship. André Karch is last authorship. Authors and Affiliations Dep … gnostic anamneses and lab results (NC, S Spike, IGRA and NAb). Institutions can apply for the data via [email protected]. Data were provided to the modelling network for severe infectious diseases in Germany (MONID [ 13 ]). Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 1800 K
Healthcare Private Placement and M&A Transactions Review Week Ending April 6, 2025 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending April … ital Partners, Soleus Capital, YK Bioventures, Ysios Capital, Berkeley Frontier Fund, LYFE Capital, Alexandria Venture Investments, The Column Group, Euclidean Capital, Schroders Capital, Willett Advisors, UC Investments and Fidelity Management & Research Company also participated in the round. The company is a developer of regenerative cell therapies designed for the treatment of chronic neurological disorders. Imbria Pharmaceuticals: The company raised $59 million in Se … n of Series A venture funding in a deal led by Accel on April 2, 2025. Together Fund, Ankitt Jain, Sachin Jain, Oscar Benavidez and Matthew Zubiller also participated in the round. The company is a developer of a revenue cycle and billing platform designed for the healthcare sector. PanTher Therapeutics: The company raised $7 million of venture funding through a combination of debt and equity on April 4, 2025. The company is a developer of a cancer treatment technology design
Social Fundraising click Log in CCI Immunotherapy Research Fund Fundraising goal $500,000.00 Donate! Recent donations (170 donations) Name Amount Andrew Dervan Janux Tx Julia Carlson Jose Alvarenga Clasp Therapeutics, Inc. Recent donations Pacific Crest Trail Thru Hiking Adventure The Pacific Crest Trail (PCT) extends 2658 miles from Campo on the southern California border with Mexico to Manning Park, British Columbia in Canada. PCT Thru Hiking Adventure to Support Cellular Immunotherapy Research In 2023 and 2024 I thru hiked the 2658 mile Pacific Crest Trail with my husband, Gib Biddle, to co … urneys in the Center for Cellular Immunotherapy at Penn. The inaugural class of grant recipients participated in a 4-day leadership skills development backpacking retreat in the California High Sierra in August of 2024, an annual event that will be supported by this fundraiser. Why the Pacific Crest Trail? The PCT is a 2658-mile wilderness trail that starts near the town of Campo on the Mexican border in California and traverses the southern Californian desert with its mounta … ct.substack.com/p/coming-soon) . If you prefer to donate through a donor advise fund, the EIN for University of Pennsylvania is: Legal Name: Trustees of the University of Pennsylvania; Employee Identification #: 23-1352685. if you prefer to send a check, please mail to the address below and direct it to the CCI Fund. If sending a check, please contact Mike Krystopolski at U Penn and we will work to ensure it is allocated to this fund, and that the donation is accounted for on … tful and insightful essays, your pioneering work in biotech, and establishing a fund to pay it forward! Julie Urvater --Julie Urvater Very inspiring and for a fantastic cause! Thanks for sharing and letting us experience it vicariously! --Tim Lowinger Well Done, Kristen! --Mark Gilbert What comes around goes around. Thanks for sharing your good KarMMa with us on the PCT and in your home. See ya out there somewhere. --Salty and Frito This is in memory of Olivier Gouedard who w
ImmuneBridge Home Technology Team News Contact Oliver Hardick, EngD Board Member Board of Directors Bio Oliver Hardick is an Engineer by training (Eng Doctorate UCL 2012), Entrepreneur by mindset (Puridify, sold to GE 2017), & Investor by trade (M Ventures). In 2013 Ollie founded Puridify, a biotech tools company, based on his academic research. He led this company as CEO through VC funding to a strong exit by GE Healthcare in 2017, interacting with biotherapeutic manufacturers globally throughout this journey. Ollie spent the subsequent 5 years at GE & Danaher Corp in leadership roles
Cell Therapy Consistency in Living Systems | Biruni Cell Therapy posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to L
Team — Ligase BioPartners Home About Team Funds News Contact Team Experienced builders at the intersection of science, medicine, and capital. The Ligase BioPartners team brings decades of expertise in life sciences venture capital, strategic guidance, and operational support needed to accelerate development of early stage innovation. Cheryl Zimberlin, Ph.D Managing Director Cheryl is the former Investment Director at M Ventures, where she led Seed and Series A investments in Calypso Biotech, Rewind Therapeutics, Outrun Therapeutics, Multitude Therapeutics, ImmuneBridge, and several other emerg … Director Shobhit is the former Managing Director of the Oncode Oncology Bridge Fund I, where he built and financed early-stage therapeutic and platform companies emerging from the Oncode Institute. Previously, he was an Investment Manager at Amsterdam Academic Ventures, focusing on company creation and early financings across life sciences and technology. Shobhit holds a Ph.D. in Immunology from the University of Amsterdam and serves on the Board of Directors of sCellgen, 51
SITC Clinical Immuno-Oncology Network (SCION) Workshop - Society for Immunotherapy of Cancer (SITC) Skip main navigation (Press Enter). Log in Toggle navigation Education & Science SITC 2026 - 41st Annual Meeting & Pre-Conference Programs Past and Future Annual Meetings Advances in Cancer Immunotherapy SITC Biotech Initiative 2026 SITC Biotech Strategic Meeting at the NYSE 2026 SITC EU Immuno-Oncology Drug Development Summit SITC Biotech Community Membership SITC Neoadjuvant Initiatives Cancer Immunotherapy Winter School Spring Scientific Collaborative Education Programs Patient & … r Development Certificate in Cancer Immunotherapy Fellowships NCI Immunotherapy Fellowship Women in Cancer Immunotherapy Network 2026 WIN Schedule Page Sparkathon SITC Clinical Immuno-Oncology Network (SCION) Workshop Clinical Trials Training and Resources Early Career Scientist (ECS) Committee Path to SITC Leadership Annual Award Nominations 2026 Rosenberg Scholars Award Publications & Guidelines Journal for ImmunoTherapy of Cancer SITC Clinical Practice Guidelines SITC Immu … trial protocols.” Arya Mariam Roy, MD Roswell Park Comprehensive Cancer Center Award Opportunities Application Process Organizers SCION FAQs Application Packet Contact Us The 2026 SITC Clinical Immuno-Oncology Network (SCION) Workshop is supported, in part, by: Merck Sharp & Dohme LLC, AstraZeneca Pharmaceuticals, Genentech USA, Inc., Sanofi US Services Inc., Chugai Foundation for Innovative Drug Discovery Science, and the Pancreatic Cancer Action Network (supporters as … ary 28, 2026). Gold Sponsor Silver Sponsor Bronze Sponsor Bronze Sponsor Travel Award Sponsor Travel Award Sponsor Application Process Application Details Selection: Selection is made by the SITC Clinical Immuno-Oncology Network (SCION) Workshop Organizers. Applicants will be notified via email of their application’s status within 10 weeks of the application deadline. Terms: SCION participants will pay a registration fee for the SCION workshop. SCION participants will cover a … tion fee includes participation in the SITC Cancer immunotherapy Winter School. Application Process: Applicants will submit a completed application form, sponsor statement (from a mentor/supervisor), an applicant statement of interest, curriculum vitae, and abstract of the proposed protocol. 90-day Reporting: Workshop attendees are required to co
ImmuneBridge Home Technology Team News Contact Dylan Morris Board Member Board of Directors Bio Dylan Morris is a Managing Director at Insight Partners, where he leads the firm’s bio practice. Dylan joined Insight in 2021 to focus on investments at the intersection of computation and biology. He loves technology-enabled approaches to drug discovery and development, new therapeutic modalities, and curative therapies. He is drawn towards novel methods of generating data and enjoys working with driven founders who agree that the primary goal is to help patients. AB: Computer Science, Harvard Cont
--> --> ImmuneBridge | Insight Partners Go to home page main-logo main-logo Why Insight? Portfolio Team Ideas Events Go Login --> --> --> --> --> main-logo-solid Why Insight? Portfolio Team Ideas Events Go Login twitter linkedin instagram ©2026 Insight Partners Go to home page main-logo About Us Contact Us Join Insight Media Newsroom LP Portal Portfolio Jobs For Enterprise Responsibility twitter linkedin instagram footer-banner-logo *The portfolio companies and portfolio company executives presented are examples of portfolio companies that Insight has worked with to assist the company ach
Why we invested in ImmuneBridge LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . … and reflecting on the year 2024 for our young… 3 Feb 12, 2025 I run a $100M VC fund for immigrants—here’s why they’re often better than those born here This article was originally published in Fortune. By Semyon Dukach, Founding Partner of One Way Ventures, a VC firm… 15 2 Comments Jan 15, 2025 What counting cards at blackjack can teach you about VC investing This article was originally published in Fast Company. By Semyon Dukach, Founding Partner of One Way Ventures, a VC…
ImmuneBridge Home Technology Team News Contact Omri Amirav-Drory, PhD Board Member Board of Directors Bio Omri Amirav-Drory is the General Partner at NFX Bio and a seasoned scientist-operator turned investor. He was the Founding CEO of Genome Compiler, which was acquired by Twist Bioscience, where he later served as Head of Corporate Development. Omri went on to found Tech.Bio, investing in and advising leading techbio companies like Mammoth Biosciences and Immunai. Now at NFX, he champions Scientist-CEOs and envisions a future where they are the standard. Contact Us [email protected] 212
About Event - 4th Donor Selection & Cell Source Summit Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2025 summit Returning December 2026 About About Event Events in the Series What’s On? Full Event Guide Why Partner Why Partner Partners Take Part Pricing & Registration Contact Us 2025 Event Guide Register Interest About About Event Events in the Series What’s On? Full Event Guide Why Partner Why Partner Partners Take Part Pricing & Registration Contact Us Returning December 2026 2025 Event Guide Register I … and C-level executives to present practical, cross-functional takeaways you can apply immediately to accelerate timelines, cut costs, and meet clinical demand. Download the Agenda What to Expect? 2 Days of Unmissable Content Including new data & actionable insights from from allogeneic leaders 8+ Hours of Networking And interactive discussion-led sessions to develop critical solutions to the most pressing challenges 14 Brand New Speakers Across analytical development, sup
ImmuneBridge Home Technology Team News Contact S. Alexander Jacobson Board Member Board of Directors Bio Alex Jacobson is a founder and investment partner of 137 Ventures. Alex is also a founding investor of ImmuneBridge, a biotech startup developing genetically enhanced immune cell therapies, and founding advisor to Armada, a startup building a distributed data center platform connected by Starlink. Alex is also on the board of advisors of Strategy Capital, the investment fund of Hamilton Helmer, author of Seven Powers. Previously, Alex was an entrepreneur-in-residence at Founders Fund, where
European B2B Startups, Startup Studio and Venture Builders | The $ Billion Bottleneck in Modern Medicine 🧬
Top 10 Oncology Capital Raises in the U.S. - April 1st-15th, 2025 -- End of the comment --> Toggle navigation Top Capital Raises CPTV CPGO About Castle Placement Team Testimonials Posts Capital Letters™ A View From The Castle® Data Room Services Capital Raising Castle Referral Program CPGO Competition CPGO I-Bank CPGO Network PE Secondary Transactions Corporate Currency® CPGO Connect New York Asset Management Corp. Call us +212.418.1180 [email protected] Top 10 Oncology Capital Raises in the U.S. – April 1st-15th, 2025 Several interesting
Interview with Nina Horowitz - 11th Innate Killer Summit Skip to content This event has run. Thank you to our speakers, sponsors, and delegates who joined us for the 2026 summit. Returning March 2027 About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Media Partners Take Part Register Interest Contact Us Previous Event Guide Register Interest About About Event FAQs Interview with Nina Horowitz Hanson Wade Products What’s On? Full Event Guide Speakers Why Partner Why Partner Partners Media Par
--> » ImmuneBridge raises funds to advance new cell-based immunotherapies --> --> ImmuneBridge raises funds to advance new cell-based immunotherapies Pharmaceutical Business review is using cookies Continue Learn More Close ☰ Search × Home About Us Add Company Advertise with us Contact us Events Suplpiers News Clinical Trials Drug Discovery Packaging & Supply Chain Production & Sales Regulation Advertise With Us Advertise on our extensive network of industry websites and newsletters. Get the PBR newsletter Sign up to our free email to get all the latest PBR news. Ho … t Enrollment Human Trials Patient Enrollment US FDA approves Avacta Group’s IND application for AVA6000 Clinical Trials Patient Enrollment AM-Pharma enrols first patients in Covid-19 phase III trial Clinical Trials Patient Enrollment Regulation Regulation Drug Filing Approvals Rejections Marketing Authorisation Patents Lawsuits Drug Filing Viatris files applications in Japan for approval of Effexor to treat GAD Regulation Drug Filing Drug Manufacturing Scholar Rock submits ap
Technology Home Technology Team News Contact Overview Source Screen Scale Overview ImmuneBridge is a first-in-class integrated screening and manufacturing platform for cell therapy development. Source There are two main approaches for allogeneic cell therapy manufacturing and both are significantly flawed. Some companies prioritize diversity, manufacturing their products using immune cells from different donors. Some companies prioritize scalability, choosing a single heavily engineered iPSC line as the perpetual source for their cell product. Both approaches sound sufficient in theory, but in … , donor, engineering, manufacturing process, and cell type for each therapeutic application. We approach this massively complex problem by screening donors, engineering constructs, and manufacturing processes in high throughput using our automated and multiplexed assay system. We evaluate the critical immune functions of potential drug candidates using assays precisely matched to target patient populations – enabling us or our partners to rank and select optimal products fo
Instagram Instagram Log In Sign Up Close Never miss a post from skim.insights Sign up for Instagram to stay in the loop. Sign up Log in skim.insights • Follow More options skim.insights 13w A biotech company just raised another $7.7 million, and ImmuneBridge is worth watching. The company is building an off-the-shelf cell therapy platform designed to make immune-cell treatments more scalable, more consistent, and ultimately more accessible. #startups #science #biotech #venturecapital #finance Load more comments cherrieabaya Verified 13w Allogenic!!! 1 like Reply dr.evolu.sean Verified 13w Them
NFX leads investment in ImmuneBridge, tackling cell therapy bottleneck | Anastasia Budinskaya posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo
ImmuneBridge | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas ImmuneBridge Website: ImmuneBridge Business Area(s) Cell and Gene Therapy Description ImmuneBridge is developing allogeneic immunotherapies for cancer. Their core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cell
ImmuneBridge Home Technology Team News Contact Home Technology Team News Contact Home Technology Team News Contact All Posts Announcements ImmuneBridge Raises $7.7M Published on March 23, 2026 ImmuneBridge Raises $7.7M to Make Scalable Cell Therapy a Reality Today, ImmuneBridge announced a $7.7M second seed round. This funding will help the company make significant progress toward unlocking cell therapy manufacturing at scale. The round was led by NFX, with participation from One Way Ventures, M Ventures, Insight Partners, LongGame Ventures, T.Rx Capital, Healthspan Capital, Sand Hill Angels,
ImmuneBridge | NFX Guild Job Board From seed to win. Content Content Team Team Companies Companies About About Focus Areas Bio Gaming Generative AI Proptech Space Fintech Marketplaces Crypto Silicon Valley Israel Europe LatAm Focus Areas Bio Gaming Generative AI Proptech Space Fintech Marketplaces Crypto Silicon Valley Israel Europe LatAm Products Signal Brieflink NFX Masterclass ChatNFX Products Signal Brieflink NFX Masterclass ChatNFX Work with the world's top founders Search jobs Explore companies Join talent network Talent My job alerts ImmuneBridge immunebridge.com Locations San Francisco
Technology Home Technology Team News Contact Overview Source Screen Scale Overview ImmuneBridge is a first-in-class integrated screening and manufacturing platform for cell therapy development. Source There are two main approaches for allogeneic cell therapy manufacturing and both are significantly flawed. Some companies prioritize diversity, manufacturing their products using immune cells from different donors. Some companies prioritize scalability, choosing a single heavily engineered iPSC line as the perpetual source for their cell product. Both approaches sound sufficient in theory, but in … , donor, engineering, manufacturing process, and cell type for each therapeutic application. We approach this massively complex problem by screening donors, engineering constructs, and manufacturing processes in high throughput using our automated and multiplexed assay system. We evaluate the critical immune functions of potential drug candidates using assays precisely matched to target patient populations – enabling us or our partners to rank and select optimal products fo
ImmuneBridge Secures $7.7M to Open Cell Therapy Manufacturing Platform to Biotech Partners Skip to main content Skip to secondary menu Skip to primary sidebar Skip to secondary sidebar Skip to footer Opinion Health IT Behavioral Health Care Coordination EMR/EHR Interoperability Patient Engagement Population Health Management Revenue Cycle Management Social Determinants of Health Digital Health AI Blockchain Precision Medicine Telehealth Wearables Life Sciences Investments M&A Value-based Care Accountable Care (ACOs) Medicare Advantage ImmuneBridge Secures $7.7M to Open Cell Therapy Manufa … Consultant Latest insightful articles delivered straight to your inbox weekly. Submit a Tip or Pitch Featured Insights Aligning IT & Clinical Teams: How to Reduce Friction and Improve Communication Most-Read Clinical Data Fidelity: The Real Blindspot in Healthcare AI Strategy KLAS 2026 EHR Market Share Report: Epic Gains as Oracle Health Faces Third Year of Losses M&A: Qualtrics Completes $6.75B Acquisition of Press Ganey Forsta Viz.ai Launches Viz Pulmonary™ Suite
Jobs at ImmuneBridge | Consider You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Sign In Powered by Consider Privacy Terms
Building Bridges to Scalable Allogeneic Cell Therapy Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel
--> --> ImmuneBridge jobs, careers, overview, and news by VentureLoop --> --> --> --> MENU Toggle navigation Home Job Search internships --> blog widget --> Login --> --> ImmuneBridge 0 Job Address , Website www.immunebridge.com Investors QB3 About --> About ImmuneBridge ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies
Interview with Nina Horowitz of ImmuneBridge Skip to main content ® Toggle navigation About Cord Blood Birth in My Country Cord Blood Value How Banks Work Infographic FAQs Family Banking Family Banks in My Country World Map Family Banks Help for families in need Public Donation The Youngest Donor How to Donate Cord Blood USA Donation Hospitals Public Banks in My Country World Map Public Banks Therapies Available Diseases Treated Clinical Trials Cord Blood Clinical Trials Cord Tissue Odds of use Milestones Cord Blood Resources Parent Brochures Delayed Cord Clamping Accreditation S
ImmuneBridge Home Technology Team News Contact Immune Bridge We use the highest possible quality starting material: young, healthy, and disease-free umbilical cord blood stem cells. This enhances therapeutic efficacy and enables intentional leveraging of nature’s innate diversity through accessing the hundreds of thousands of umbilical cord blood units currently frozen in public banks. Our ML-powered screening system enables affordable and efficient sampling of donors, engineering constructs, manufacturing processes, and cell types to identify or design optimal clinical candidates for almost a … stems, and maintaining and evolving large, complex codebases. She is excited to apply her technical background to the healthcare space and continue building impactful solutions. BA: University of California, Berkeley - Computer Science Kimberly Zai Machine Learning and Data Engineer Board of Directors Omri Amirav-Drory is the General Partner at NFX Bio and a seasoned scientist-operator turned investor. He was the Founding CEO of Genome Compiler, which was acquired by Twist Bi … link. Alex is also on the board of advisors of Strategy Capital, the investment fund of Hamilton Helmer, author of Seven Powers. Previously, Alex was an entrepreneur-in-residence at Founders Fund, where he led the diligence processes for investments in SpaceX. He also founded Shop.com, a shopping and comparison website, which he eventually sold to Altura Ventures, Virtual Office, one of the first companies to register commercially valuable domain names, and Interband, an adve
ImmuneBridge Tackles Cell Therapy Bottleneck with Scalable Solution | Michael Langer posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig
Case Study: ImmuneBridge Transitions from Point Product to Enterprise-Class ELN Solution with Sapio Sciences | Sapio Sciences Sapio Sciences Login Products Sapio Platform – Configurable and AI-Native Unify your lab. The industry’s first Science-aware™ agentic AI lab platform. Sapio LIMS® – Laboratory Information Management System A no-code LIMS system made for scientists and configurable lab workflow. Sapio ELN® – Electronic Lab Notebook An AI-native electronic lab notebook that flexes to the needs of every scientific experiment. Sapio Scientific Data Cloud SDMS Unifies all scientific data and … Artificial Intelligence for Drug Research and Development AI in Pharmaceutical Apply AI Co-scientist to the Pharmaceutical Industry AI for Life Sciences Data Security AI Data Protection and Security One platform for every lab workflow — built to advance science, not just record it. Schedule Your Demo Solutions Research & Development Biotech R&D Enjoy radical configurability and unprecedented scale. Chemistry R&D A unified solution for small molecule discovery. … rt and timely addressing of feedback were crucial in configuring the system and rolling it out to scientists. Key Features Critical functionality delivered by the Sapio ELN includes: No-code configurability that makes the ELN easily usable by scientists for data management, data access/search, experiment tracking, and data visibility and enables analysis. Sample and materials management. Easy integration of various technologies, including different software systems and instru
ImmuneBridge Home Technology Team News Contact Thomas Farrell, MBA Board Member Board of Directors Bio Tom Farrell has a twenty-five year track record as a serial biotech company builder and executive. He has been the founding CEO of two public cell therapy companies, most recently Artiva Biotherapeutics, a leader in off-the-shelf primary NK cell therapies for autoimmune disease and cancer, where he raised a $78 million Series A and supported the company through a successful crossover financing, major strategic partnership with Merck, and journey to a first S-1 filing. Previously, Tom was Pres
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
ImmuneBridge Home Technology Team News Contact Immune Bridge We use the highest possible quality starting material: young, healthy, and disease-free umbilical cord blood stem cells. This enhances therapeutic efficacy and enables intentional leveraging of nature’s innate diversity through accessing the hundreds of thousands of umbilical cord blood units currently frozen in public banks. Our ML-powered screening system enables affordable and efficient sampling of donors, engineering constructs, manufacturing processes, and cell types to identify or design optimal clinical candidates for almost a … stems, and maintaining and evolving large, complex codebases. She is excited to apply her technical background to the healthcare space and continue building impactful solutions. BA: University of California, Berkeley - Computer Science Kimberly Zai Machine Learning and Data Engineer Board of Directors Omri Amirav-Drory is the General Partner at NFX Bio and a seasoned scientist-operator turned investor. He was the Founding CEO of Genome Compiler, which was acquired by Twist Bi … link. Alex is also on the board of advisors of Strategy Capital, the investment fund of Hamilton Helmer, author of Seven Powers. Previously, Alex was an entrepreneur-in-residence at Founders Fund, where he led the diligence processes for investments in SpaceX. He also founded Shop.com, a shopping and comparison website, which he eventually sold to Altura Ventures, Virtual Office, one of the first companies to register commercially valuable domain names, and Interband, an adve